nach oben

Erschienen in:

06.06.2016 | Original Research

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation

verfasst von: Adam H. Buchanan, Corrine I. Voils, Joellen M. Schildkraut, Catherine Fine, Nora K. Horick, P. Kelly Marcom, Kristi Wiggins, Celette Sugg Skinner

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Identifying unaffected women with a BRCA mutation can have a significant individual and population health impact on morbidity and mortality if these women adhere to guidelines for managing cancer risk. But, little is known about whether such women are adherent to current guidelines. We conducted telephone surveys of 97 unaffected BRCA mutation carriers who had genetic counseling at least one year prior to the survey to assess adherence to current guidelines, factors associated with adherence, and common reasons for performing and not performing recommended risk management. More than half of participants reported being adherent with current risk management recommendations for breast cancer (69 %, n = 67), ovarian cancer (82 %, n = 74) and both cancers (66 %, n = 64). Older age (OR = 10.53, p = 0.001), white race (OR = 8.93, p = 0.019), higher breast cancer genetics knowledge (OR = 1.67, p = 0.030), higher cancer-specific distress (OR = 1.07, p = 0.002) and higher physical functioning (OR = 1.09, p = 0.009) were significantly associated with adherence to recommended risk management for both cancers. Responses to open-ended questions about reasons for performing and not performing risk management behaviors indicated that participants recognized the clinical utility of these behaviors. Younger individuals and those with lower physical functioning may require targeted interventions to improve adherence, perhaps in the setting of long-term follow-up at a multi-disciplinary hereditary cancer clinic.

American Society of Clinical Oncology (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397–2406. doi:10.1200/jco.2003.03.189.CrossRef

Berliner, J. L., Fay, A. M., & Practice Issues Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk Counseling Special Interest, G (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 16(3), 241–260.CrossRefPubMed

Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B., & Tillmanns, T. (2013). NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling, 22(2), 155–163.CrossRefPubMed

Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet Part A, 118(3), 201–209.CrossRef

Bradbury, A. R., Ibe, C. N., Dignam, J. J., Cummings, S. A., Verp, M., White, M. A., et al. (2008). Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine, 10(3), 161–166.CrossRefPubMedPubMedCentral

Buchanan, A. H., Skinner, C. E., Calingaert, B., Schildkraut, J. M., King, R. H., & Marcom, P. K. (2009). Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Commun Oncol(6), 70–77.

Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., et al. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA, 277(12), 997–1003.CrossRefPubMed

Caiata-Zufferey, M., & Pagani, O. (2015). Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genetics in Medicine, 17(9), 726–732. doi:10.1038/gim.2014.183.CrossRefPubMed

Calzone, K. A., Prindiville, S. A., Jourkiv, O., Jenkins, J., DeCarvalho, M., Wallerstedt, D. B., et al. (2005). Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. Journal of Clinical Oncology, 23(15), 3455–3464.CrossRefPubMed

Caplan, L. S., McQueen, D. V., Qualters, J. R., Leff, M., Garrett, C., & Calonge, N. (2003). Validity of women’s self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiology, Biomarkers & Prevention, 12(11 Pt 1), 1182–1187.

CDC. (2014, September 8, 2014). Office of Public Health Genomics - Genomic Tests and Family History by Levels of Evidence. Retrieved April 28, 2015, from http://www.cdc.gov/genomics/gtesting/tier.htm

Chagpar, A. B., Polk Jr., H. C., & McMasters, K. M. (2008). Racial trends in mammography rates: a population-based study. Surgery, 144(3), 467–472.CrossRefPubMed

Chen, S., & Parmigiani, G. (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology, 25(11), 1329–1333.CrossRefPubMedPubMedCentral

Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93–105.CrossRefPubMed

Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA, 296(2), 185–192.CrossRefPubMed

Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., et al. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15), 1547–1553.CrossRefPubMedPubMedCentral

Friebel, T. M., Domchek, S. M., Neuhausen, S. L., Wagner, T., Evans, D. G., Isaacs, C., et al. (2007). Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer, 7(11), 875–882.CrossRefPubMed

Garcia, C., Wendt, J., Lyon, L., Jones, J., Littell, R. D., Armstrong, M. A., et al. (2014). Risk management options elected by women after testing positive for a BRCA mutation. Gynecologic Oncology, 132(2), 428–433.CrossRefPubMed

Hadley, D. W., Jenkins, J. F., Dimond, E., de Carvalho, M., Kirsch, I., & Palmer, C. G. (2004). Colon Cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 22(1), 39–44.CrossRefPubMed

Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics, 42(2), 377–381.CrossRefPubMed

Horowitz, M. J., Wilner, N., & Alvarez, W. (1979). Impact of event scale: a measure of subjective stress. Psychosomatic Medicine, 41(3), 209–218.CrossRefPubMed

Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288.CrossRefPubMed

Hughes, C., Lerman, C., Schwartz, M., Peshkin, B., Wenzel, L., Narod, S., et al. (2002). All in the family: evaluation of the processand content of sisters’ communication about BRCA1 and BRCA2 genetic test results. American Journal of Medical Genetics, 107, 143–150.CrossRefPubMed

Julian-Reynier, C., Bouhnik, A. D., Mouret-Fourme, E., Gauthier-Villars, M., Berthet, P., Lasset, C., et al. (2010). Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine, 12(12), 801–807.CrossRefPubMed

Khoury, M. J., Coates, R. J., & Evans, J. P. (2010). Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genetics in Medicine, 12(11), 680–683.CrossRefPubMed

King, E. S., Rimer, B. K., Trock, B., Balshem, A., & Engstrom, P. (1990). How valid are mammography self-reports? American Journal of Public Health, 80(11), 1386–1388.CrossRefPubMedPubMedCentral

Kinney, A. Y., Simonsen, S. E., Baty, B. J., Mandal, D., Neuhausen, S. L., Seggar, K., et al. (2006). Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. Journal of Genetic Counseling, 15(4), 293–305.CrossRefPubMed

Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 28(2), 222–231.CrossRefPubMed

Leonarczyk, T. J., & Mawn, B. E. (2015). Cancer risk management decision making for BRCA+ women. Western Journal of Nursing Research, 37(1), 66–84.CrossRefPubMed

Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Preventive Medicine, 31(1), 75–80.CrossRefPubMed

Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., Seynaeve, C., et al. (2002). One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Research and Treatment, 73(2), 97–112.CrossRefPubMed

Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Tilanus-Linthorst, M. M., Wagner, A., et al. (2000). Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355(9220), 2015–2020.CrossRefPubMed

Meijers-Heijboer, H., Brekelmans, C. T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. (2003). Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 21(9), 1675–1681.CrossRefPubMed

Metcalfe, K. A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., et al. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 122(9), 2017–2022.CrossRefPubMedPubMedCentral

Miranda, P. Y., Tarraf, W., & Gonzalez, H. M. (2011). Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Research and Treatment, 128(2), 535–542.CrossRefPubMed

Montano, D. E., & Phillips, W. R. (1995). Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. American Journal of Public Health, 85(6), 795–800.CrossRefPubMedPubMedCentral

NCCN. (2000, 06/01/00). NCCN Practice Guidelines: Genetics/Familial High-Risk Cancer Screening. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2001, 04/19/01). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Screening: Breast Version 1.2001. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2002, 04/22/02). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast Version 1.2002. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2005, 09/09/05). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2005. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2006, 12/14/05). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2006. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2010, 03/08/10). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2010. Retrieved February 11, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2012, 05/02/12). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2012. RetrievedNCCN August 16, 2012, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2003, 07/28/03). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2003. Retrieved February, 2011, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

NCCN. (2015, 3/30/15). Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2015. Retrieved April 30, 2015, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf

O’Neill, S. C., Valdimarsdottir, H. B., Demarco, T. A., Peshkin, B. N., Graves, K. D., Brown, K., et al. (2010). BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Research and Treatment, 124(3), 755–764.CrossRefPubMedPubMedCentral

Onwuegbuzie, A. (2003). Effect sizes in qualitative research: a prolegomenon. Quality & Quantity, 37(4), 393–409.CrossRef

Pal, T., Lee, J. H., Besharat, A., Thompson, Z., Monteiro, A. N., Phelan, C., et al. (2014). Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clinical Genetics, 85(1), 49–53.CrossRefPubMed

Patenaude, A. F., Dorval, M., DiGianni, L. S., Schneider, K. A., Chittenden, A., & Garber, J. E. (2006). Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. Journal of Clinical Oncology, 24(4), 700–706.CrossRefPubMed

Peshkin, B. N., Schwartz, M. D., Isaacs, C., Hughes, C., Main, D., & Lerman, C. (2002). Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiology, Biomarkers & Prevention, 11(10 Pt 1), 1115–1118.

Petrucelli, N., Daly, M. B., & Feldman, G. L. (2013). BRCA1 and BRCA2 hereditary breast and ovarian cancer. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, T. D. Bird, C. T. Fong, R. J. H. Smith & K. Stephens (Eds.), GeneReviews(R). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. All rights reserved.

Phillips, K. A., Jenkins, M. A., Lindeman, G. J., McLachlan, S. A., McKinley, J. M., Weideman, P. C., kConFab, I. (2006). Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clinical Genetics, 70(3), 198–206.

Rauscher, G. H., Johnson, T. P., Cho, Y. I., & Walk, J. A. (2008). Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 17(4), 748–757.CrossRef

Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ‘t Veer, L., Garber, J. E., Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. Journal of Clinical Oncology, 22(6), 1055–1062.

Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80–87.CrossRefPubMedPubMedCentral

Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 21(2), 151–161.CrossRefPubMed

Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical Oncology (2009). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901..CrossRef

Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology, 20(5), 1260–1268.CrossRefPubMed

Schmeler, K. M., Sun, C. C., Bodurka, D. C., White, K. G., Soliman, P. T., Uyei, A. R.,. Lu, K. H. (2006). Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstetrics and Gynecology, 108(3 Pt 1), 515–520.CrossRefPubMed

Schwartz, M. D., Isaacs, C., Graves, K. D., Poggi, E., Peshkin, B. N., Gell, C., et al. (2012). Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer, 118(2), 510–517.CrossRefPubMed

Schwartz, M. D., Kaufman, E., Peshkin, B. N., Isaacs, C., Hughes, C., DeMarco, T., et al. (2003). Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. Journal of Clinical Oncology, 21(21), 4034–4041.CrossRefPubMed

Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Halbert, C. H., DeMarco, T., et al. (2004). Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. Journal of Clinical Oncology, 22(10), 1823–1829.CrossRefPubMed

Sidon, L., Ingham, S., Clancy, T., Clayton, R., Clarke, A., Jones, E. A., et al. (2012). Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 106(4), 775–779.CrossRefPubMed

Skinner, C., Rawl, S., Moser, B., Buchanan, A., Scott, L., Champion, V., et al. (2005). Impact of the cancer risk intake system on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. Journal of General Internal Medicine, 20(4), 360–365.CrossRefPubMed

Skinner, C. S., Buchanan, A., Champion, V., Monahan, P., Rawl, S., Springston, J., et al. (2011). Process outcomes from a randomized controlled trial comparing tailored mammography interventions delivered via telephone vs. DVD. Patient Educ Couns, 85(2), 308–312.CrossRefPubMed

Skinner, C. S., Tiro, J., & Champion, V. L. (2015). The health belief model. In K. Glanz, B. K. Rimer, & K. Viswanath (Eds.), Health Behavior Theory, Research, and Practice (5th ed., pp. 75–94). San Francisco, CA: Jossey-Bass.

Spielberger, C. D., Gorsuch, R., Lushene, R., & al., e. (1983). State-Trait Anxiety Inventory for Adults: Sampler Set - Manual, Test, Scoring Key. Palo Alto, CA: Mind Garden.

Tinley, S. T., Houfek, J., Watson, P., Wenzel, L., Clark, M. B., Coughlin, S., et al. (2004). Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. American Journal of Medical Genetics. Part A, 125A(1), 5–11.CrossRefPubMed

Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 13(2), 83–114.CrossRefPubMed

Uyei, A., Peterson, S. K., Erlichman, J., Broglio, K., Yekell, S., Schmeler, K.,. Arun, B. (2006). Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer, 107(12), 2745–2751.CrossRefPubMed

Ware Jr., J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMed

Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., et al. (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Journal of Clinical Oncology, 29(13), 1664–1669.CrossRefPubMedPubMedCentral

Watson, M., Kash, K. M., Homewood, J., Ebbs, S., Murday, V., & Eeles, R. (2005). Does genetic counseling have any impact on management of breast cancer risk? Genetic Testing, 9(2), 167–174.CrossRefPubMed

Willis, G. B. (2005). Cognitive interviewing. Thousand Oaks, CA: SAGE Publications.CrossRef

Yerkes, R. M., & Dodson, J. D. (1908). The relation of strength of stimulus to rapidity of habit-formation. Journal of Comparative Neurology and Psychology, 18, 459–482.CrossRef

Zapka, J. G., Bigelow, C., Hurley, T., Ford, L. D., Egelhofer, J., Cloud, W. M., et al. (1996). Mammography use among sociodemographically diverse women: the accuracy of self-report. American Journal of Public Health, 86(7), 1016–1021.CrossRefPubMedPubMedCentral

Titel: Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation
verfasst von: Adam H. Buchanan
Corrine I. Voils
Joellen M. Schildkraut
Catherine Fine
Nora K. Horick
P. Kelly Marcom
Kristi Wiggins
Celette Sugg Skinner
Publikationsdatum: 06.06.2016
Verlag: Springer US
Erschienen in: Journal of Genetic Counseling / Ausgabe 1/2017
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-016-9981-6

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Patient Recall, Interpretation, and Perspective of an Inconclusive Long QT Syndrome Genetic Test Result

A Review of the Genetics of Intracranial Berry Aneurysms and Implications for Genetic Counseling

Impact of Genetic Testing and Family Health History Based Risk Counseling on Behavior Change and Cognitive Precursors for Type 2 Diabetes

“The Top Priority Is a Healthy Baby”: Narratives of Health, Disability, and Abortion in Online Pregnancy Forum Discussions in the US and China

Is there a Role for Genetic Counselors in Prenatal Paternity Testing? – an Assessment Based on Audit of 13 years of Clinical Experience in South Australia

Notable Carrier Risks for Individuals Having Two Copies of SMN1 in Spinal Muscular Atrophy Families with 2-copy Alleles: Estimation Based on Chinese Meta-analysis Data

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie